Background. Clinical staging of esophageal cancer has improved with positron-emission tomography/computed tomography and endoscopic ultrasound imaging. Despite such progress, small single-center studies have questioned the reliability of clinical staging of T2 N0 esophageal cancer. This study broadly examines the adequacy of clinical staging of T2 N0 disease using The Society of Thoracic Surgeons database.
Methods. We retrospectively studied 810 clinical stage T2 N0 patients from 2002 to 2011, with 58 excluded because of incomplete pathologic staging data. Clinical stage, pathologic stage, and preoperative characteristics were recorded. Logistic regression analysis was used to identify factors associated with upstaging at the time of surgical intervention.
Results. Among 752 clinical stage T2 N0 patients, 270 (35.9%) received induction therapy before the operation. Of 482 patients who went directly to surgical intervention, 132 (27.4%) were confirmed as pathologic T2 N0, 125 (25.9%) were downstaged (ie, T0-1 N0), and 225 (46.7%) were upstaged at the operation (T3-4 N0 or Tany N1-3). Exclusive tumor upstaging (ie, pathologic T3-4 N0) accounted for 41 patients (18.2%), whereas exclusive nodal upstaging (ie, pathological T1-2 N1-3) accounted for 100 (44.5%). Combined tumor and nodal upstaging (ie, pathological T3-4 N1-3) accounted for 84 patients (37.3%). Among patients who received induction therapy, 103 (38.1%) were upstaged vs 225 (46.7%) without induction therapy (p [ 0.026). Comparing the induction therapy group and the primary surgical group, postoperative 30-day mortality (3.7% vs 3.7%, p > 0.99) and morbidity (46.3% vs 45%, p [ 0.76) were similar.
Conclusions. Despite advances in staging techniques, clinical staging of T2 N0 esophageal cancer remains unreliable. Recognizing T2 N0 as a threshold for induction therapy in esophageal cancer, many surgeons have opted to treat T2 N0 disease with induction therapy, even though one-quarter of these patients will be pathologic T1 N0. Although this study demonstrated similar perioperative morbidity and mortality with and without induction therapy, further study is needed to examine the effect of upstaging on long-term survival.
(Ann Thorac Surg 2013;96:382-90) Ó 2013 by The Society of Thoracic Surgeons W hile there is debate regarding the appropriate treatment of T1 carcinomas limited to the esophageal mucosa, submucosal tumors (ie, T1b) are generally treated with primary resection without induction therapy [1] . In contrast, locally advanced but nonmetastatic esophageal carcinomas (T3 N1-3) are generally approached with induction chemoradiotherapy, followed by resection.
The premise of this approach is based on the increased likelihood of occult systemic disease with increasing tumor size and nodal involvement. Controversy may still exist regarding the role of induction therapy in locally advanced disease, but there are increasing data to suggest a survival advantage with a multimodality approach [2] [3] [4] [5] . Historically, clinical T2 N0 disease has been approached with primary surgical intervention as the standard treatment. However, concern over the potential presence of occult nodal disease has brought into question the role of induction therapy vs a primary operation for this small subset of patients.
Recent revisions in the staging system have highlighted the prognostic significance of accurate pathologic staging for esophageal carcinoma [6, 7] . Depth of tumor invasion and nodal disease are the two most important factors in this staging. These factors are more easily determined in pathologic specimens after resection but are also important in guiding treatment decisions before surgical intervention.
The addition of positron-emission tomography (PET)/ computed tomography scans and endoscopic ultrasound (EUS) imaging has improved our ability to clinically stage esophageal cancer, and both are standard recommended staging tools in the National Comprehensive Cancer Network clinical practice guidelines [8] . The addition of EUS has improved clinical staging, but the accuracy is lower for early-stage lesions (ie, T1-2 N0) vs advancedstage lesions (ie, T3 N1-3) [9] [10] [11] [12] .
The issues outlined above have brought into question the reliability of current clinical staging techniques in T2 N0 esophageal cancer and the relative role of multimodality therapy in this subset of patients. Important work by Rice and colleagues [9, 13] initially highlighted the inaccuracy of clinically staging of T2 N0 esophageal carcinoma in a small series of patients. This and other single-center studies questioning the accuracy of clinical T2 N0 esophageal cancer have been limited by small sample size [9, [14] [15] [16] .
In this study, we used The Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSDB) to overcome the limitation of small sample size that has plagued other studies. Using the database, we investigated the accuracy of clinical staging of T2 N0 esophageal cancer, examined current practice patterns in terms of treatment regimens, and examined the effect of induction therapy on perioperative morbidity and death in this subset of clinically staged T2 N0 patients.
Patients and Methods

Patient Population
All patients with clinical stage T2 N0 who underwent esophageal resection between January 2002 and December 2011 were retrospectively identified using the STS GTSDB database. Of 6,886 patients who underwent esophagectomy for esophageal cancer, 810 were classified as clinical stage T2 N0. We excluded data for 58 patients because of incomplete pathologic staging. Clinical stage (c), pathologic stage (p), preoperative demographics and comorbidities, perioperative characteristics, and 30-day morbidity and death were recorded. There were two versions of STS GTSD: version 2.07 spanned the period 2002 to 2007, and version 2.081 spanned 2008 to 2011. Tumor histology, histologic grade, and tumor location were not defined in version 2.07 but were included in version 2.081.
All study patients had biopsy specimen-proven esophageal cancer. Patients with adenocarcinoma or squamous cell carcinoma were included. Clinical and pathologic staging definitions were defined by the 6th Edition of the American Joint Committee on Cancer for staging esophageal cancer for version 2.07 and the 7th Edition for version 2.081, once this became available [7] . The study patients underwent primary surgical resection or received induction therapy, followed by resection.
Clinical stage and pathologic stage are required fields in the STS GTSDB and were reviewed for the purposes of this study. Neither a PET/computed tomography nor an EUS were required fields within the database, although we assumed that most patients underwent these staging tests.
Statistical Methods
Descriptive statistics for continuous variables are expressed as mean AE standard deviation and categoric data as counts and proportions. The Fisher exact test was used to analyze differences among the categoric data. Logistic regression analysis was used to identify covariates (among baseline patient variables) associated with upstaging. True positive (TP), false positive (FP), true negative (TN), and false negative (FN) were used to calculate sensitivity as TP/(TP þ FN); specificity as TN/ (TN þ FP), positive predictive value as TP/(TP þ FP), negative predictive value as TN/(TN þ FN), and accuracy
Values of p of less than 0.05 were considered statistically significant. Analyses were calculated using SAS software (SAS Institute, Carey, NC) and R software (The R Project for Statistical Computing, http://www.r-project.org/).
Results
From the STS GTSD, we identified 810 patients clinically staged as cT2 N0 who underwent resection between January 2002 and December 2011, with 58 excluded because of incomplete pathologic staging. Table 2 outlines the distribution of pathologic stages for cT2 N0 patients. To exclude the confounding issue of the effect of induction therapy on pathologic staging, we specifically analyzed the subset of 482 cT2 N0 patients who did not undergo induction therapy. Of 482 patients that went directly to surgical resection, 132 (27.4%) were confirmed as pT2 N0, 125 (25.9%) were downstaged (ie, T0-1 N0), and 225 (46.7%) were upstaged (T3-4 N0 or Tany N1-3). Exclusive tumor upstaging (ie, pT3-4 N0) accounted for 18.2% (n ¼ 41), and exclusive nodal upstaging (ie, pT1-2 N1-3) accounted for 44.5% (n ¼ 100). Combined tumor and nodal upstaging (ie, pT3-4N1-3) accounted for 37.3% (n ¼ 84); thus, nodal descriptor upstaging accounted for 81.8% (n ¼ 184). Figure 1 outlines the annual incidence of cT2 N0 esophageal cancer and the a Zubrod score assessed as 0, normal activity, no symptoms; 1, symptoms but fully ambulatory; 2 , symptoms but in bed < 50% of the time; 3, symptoms but in bed 50% to 100% of the time; 4, bedridden; 5, moribund.
ASA ¼ American Society of Anesthesiology; SD ¼ standard deviation.
proportion of cT2 N0 patients receiving induction therapy from 2001 to 2012. Although the incidence of cT2 N0 disease remained relatively constant during the study period as a proportion of all clinically staged esophageal cancers, the proportion of cT2 N0 patients who received induction appeared to be on an upward trend during the past few years. Table 3 outlines the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for cT2 N0 diagnosis among patients undergoing operations without induction therapy. The overall accuracy for the cT2 primary tumor diagnosis was 76.6%, whereas the accuracy of the cN0 nodal diagnosis was 74.4%. This is in comparison with the 79.6% accuracy of the cT2 N0 diagnosis outlined in Table 3 .
Patients who received induction therapy had a slightly different pattern of discordance between clinical and pathologic staging compared with the primary surgical group (Table 2 ). In the induction group, 84 patients (31.1%) were downstaged to pT0-1 N0 compared with 125 (25.9%) in the surgical group (p ¼ 0.15). Fewer patients had pathologic upstaging in the induction therapy group (31.8%) vs the primary surgery group (46.7%, p ¼ 0.026). When the induction therapy and operative group were compared, upstaging occurred due to tumor (T) alone (27.2% induction vs 18.2% surgical), nodal disease (N) alone (36.9% vs 44.4%) and T and N (35.9% vs 37.3%). Among patients who were upstaged at operation from cT2 N0, nodal upstaging accounted for 81.7% of upstaging in the primary surgical group vs 72.7% in the induction therapy group (p ¼ 0.09). Interestingly, 39 of the 40 patients who had T0 N0 tumors in the final pathologic assessment were in the induction therapy group and were likely a result of complete pathologic response. The incidence of complete pathologic response in the induction group was 14.4% (39 of 270).
The 30-day mortality was 3.7% in the induction therapy group (10 of 270) and in the primary surgical group (18 of 482, p > 0.99). Furthermore, no difference was detected in the overall complication rate between the induction therapy group and the primary surgical group (46.3% vs 45%, p ¼ 0.76; Table 4 ). Anastomotic complications requiring surgical intervention were more common in the primary surgical group than in the induction therapy group (7.3% vs 3.0%, p ¼ 0.014). Furthermore, the incidence of any complication did not differ between patients who were clinically understaged vs those who were appropriately staged or overstaged.
We examined the data for patients who underwent resection without induction therapy in an attempt to identify factors associated with discrepancies between clinical and pathologic staging. In this group, 182 patients (86.3%) had adenocarcinoma and 29 (13.7%) had squamous cell carcinoma. The grade distribution was Gx in 13 (6.1%), G1 in 24 (11.2%), G2 in 90 (42.1%), G3 in 85 (39.7%), and G4 in 2 (0.9%).
Pathologic type of tumor was not associated with pathologic upstaging among cT2 N0 patients. Univariate regression analysis showed histologic tumor grade, sex, Zubrod score, and the absence of prior thoracic procedures were associated with tumor upstaging. However, multivariate analysis found only male sex, higher Zubrod score, and absence of prior thoracic surgical procedures were associated with tumor upstaging at final pathology (Table 5 ). Histologic tumor grade was not included in the multivariate analysis because it was only reported in 
Comment
Although the techniques of clinical staging cannot be confirmed within the current versions of the GTSD, this study confirms the findings presented in previous singlecenter studies regarding the inaccuracy of clinical staging of T2 N0 esophageal cancer [9, [14] [15] [16] . These data showed the reliability of the cT2 N0 diagnosis was poor, with only 27.4% confirmed pT2 N0. Although 46.7% were apparently understaged and ultimately upstaged at operation, 25.9% were clinically overstaged and ultimately downstaged at operation to pT0-1 N0. In a similar study by Rice and colleagues [9] among 53 cT2 N0 patients, only 13% were pT2 N0, whereas 55% were downstaged at operation (pT0-1 N0) and 32% were upstaged [9] . Similar studies of cT2 N0 disease have also been limited by the small sample size, given the infrequency of this clinical stage As with other small studies, most patients who were clinically understaged were misstaged due to occult nodal disease [9, 14] . Specifically, occult nodal disease played a role in 81.8% of the clinically understaged patients. Unfortunately, details on clinical staging techniques are not a required field within the database. Thus, we do not know the specifics of how EUS was performed or if EUS-fine needle aspiration (FNA) was used consistently. Performance of EUS-FNA improves the specificity and the sensitivity for identification of nodal metastases vs the use of EUS clinical criteria alone [17, 18] . Performance of FNA of a subclinical lymph node that may contain metastatic disease will improve the sensitivity of EUS with no additional risk added to the procedure. Thus, more consistent use of EUS-FNA in these presumed clinical T2 N0 patients is a potential area of improvement in the assessment of nodal disease.
Regarding the 18.2% of patients who were understaged because of an inaccurate assessment of the depth of tumor invasion alone, a more meticulous approach to the ultrasound evaluation of the entire lesion may help to limit this problem. Careful evaluation of the entire lesion with use of higher-frequency probes that provide greater detail of the layers of the esophagus (12 or 20 MHz) may be an appropriate approach to patients initially assessed as clinical T1-2 N0 [19] . Adding a more detailed assessment with higher-frequency probes would seem reasonable when the decision to offer induction therapy is affected directly by the clinical stage.
Proportionately fewer patients in this study were upstaged at operation after induction therapy compared with those who underwent primary resection. This is presumably multifactorial, although induction therapy likely has a beneficial effect on tumor eradication and clearing of nodal metastases. Alternatively, given the limitation of the database capturing only surgical patients, there may be a subset whose disease progressed during the administration of induction therapy or who failed to come to resection because of treatment-related morbidity. The proportion of patients who are intended to undergo resection after induction therapy, but who do not make it to the operation, is generally small and often related to disease progression [20, 21] . Disease progression with induction therapy presumably would be less likely in cT2 N0 disease than in more locally advanced disease.
Despite the concept that limited disease (ie, T1-2 N0) is appropriately treated with primary surgical therapy, it appears that surgeons' perceptions of the unreliable staging of T2 N0 has prompted a more prolific use of induction therapy in these patients. Overall, 36% received some sort of induction regimen, although in the final year, 53% received induction therapy. In earlier publications of cT2 N0 disease, the percentage that received induction therapy was small, ranging from 5% to 13% [13, 14] . Given the high incidence of occult nodal disease and the unreliability of clinical staging of T2 N0 disease, some authors have advocated for routine administration of induction therapy in this population [15, 16] . Our data confirm the inaccuracy of clinical staging, but this broad approach of offering induction therapy to all of these patients would mean that more than 50% of those treated in this manner would have limited disease: 26% with T1 N0, and 27.4% with T2 N0 disease. The ultimate question regarding the management of this subset of patients is whether the survival benefit of offering induction therapy to cT2 N0 patients outweighs the risk and cost associated with induction treatment. Unfortunately, a significant limitation of this study is that long-term survival is not currently a component of the STS database.
From the current STS data presented here, there was no difference in the 30-day rates of mortality or morbidity after resection, with or without induction therapy. Some studies have demonstrated higher perioperative morbidity among patients receiving induction therapy before esophageal resection [22] . There is some controversy regarding the effect of induction therapy on perioperative morbidity, and such an impact may be more pronounced in patients with more advanced disease vs more localized disease. This is one piece of the puzzle that would favor induction therapy in this group.
The more obvious answer to what treatment we offer these patients would be to simply improve the accuracy of clinical staging in this population. Univariate analysis showed increasing histologic tumor grade (ie, more poorly differentiated tumors) was associated with pathologic upstaging, although this was not analyzed in the multivariate model because of incomplete data, as described. This is congruent with previous findings from our single-center study on cT1-2 N0 disease [14] . From the multivariate analysis, we found that male sex and a higher Zubrod functional score (worse functional status) was associated with upstaging at resection.
Another limitation of the STS database for the purposes of this study was the inconsistent recording of some factors that could potentially affect upstaging. Such factors may include tumor length and PET uptake in the primary tumor, which has previously been shown to be predictive of upstaging in cT1-2 N0 patients [14] .
Our use of the STS GTSD makes this the first largescale study of clinical staging inaccuracies among patients with presumably limited disease. Despite the current limitations of the database and the lack of granularity regarding clinical staging techniques, improvements in clinical staging are clearly necessary to guide therapy. Technical improvements in clinical staging techniques as well as the potential use of surrogate markers to supplement clinical staging may improve the accuracy of staging of early esophageal cancers. Additional efforts to improve clinical staging would seem to be more cost efficient, and perhaps safer, than broadly treating all cT2 N0 patients with induction therapy. Alternatively, however, the equivalent rate of perioperative morbidity and mortality would favor the routine use of induction therapy in light of the high rate of occult nodal disease. Until we can confirm improvements in clinical staging, however, further studies from multiple institutions are necessary to assess the relative survival benefit of induction therapy in this subset of patients.
DISCUSSION
DR CAMERON D. WRIGHT (Boston, MA): I would like to congratulate Dr Crabtree on an excellent presentation; very thoughtful and clear. I would also like to thank him and his colleagues for providing me a manuscript in a timely fashion. The manuscript is elegantly written, with a very thorough analysis of both the data and a discussion of the findings.
There are two obvious limitations within the General Thoracic Database that pertain to this report. One is that prior to the current version of the database, we did not collect the method of staging of esophageal cancer. So it is unknown how many patients had esophageal ultrasound (EUS) vs computed tomography (CT) vs positron-emission tomography (PET)-CT in determining this T2 N0 clinical staging status. Furthermore, as he mentioned at the conclusion, we don't have a survival analysis to know if it made any difference. The message of this paper is clear, though. Like Dr Rice's seminal report in 2007, where only approximately 10% of patients were correctly staged, only onequarter of the patients that we clinically stage as T2 N0 have the correct stage assigned; furthermore, most of them are seriously understaged.
I have two questions. Do you have a suggested strategy to refine the stage estimate when a T2 N0 lesion is diagnosed, perhaps by using a higher megahertz ultrasound probe to better delineate the T1 T2 interface? In the end, this is the most important aspect of this staging where we want to get it right. We want to make sure that we don't give induction therapy to T1 N0 patients.
DR CRABTREE: Dr Wright, thank you. That is an excellent question. I think certainly to delineate the different tumor stages between T1 and T2 or T2 and T3 that a higher frequency probe would intuitively allow us to see that subtle interface better. Some studies, however, have suggested that it is not the panacea. The probe is a little bit more difficult to use; it is a smaller probe. So sometimes if it is in a dilated esophagus, there is a lot of air around it making visualization more difficult. So while you might have better resolution, it wouldn't solve all of the problems.
There were some things that we couldn't look at in the database that might be clinical predictors. One that wasn't in the multivariate analysis, because it wasn't included throughout the database, was tumor differentiation. Poorly differentiated tumors were more likely to be clinically understaged. Another thing would be tumor length. As you can imagine, the longer the tumor the more room for error. Also, the standardized uptake value uptake by PET is another factor we identified in a previous small study that could potentially predict clinical understaging, although we were not able to evaluate that here. Certainly, in addition to using a higher frequency probe because of the missed advanced tumor stage, I think more liberal use of fine needle aspiration at the time of EUS would be a very important factor as well.
DR WRIGHT: Thank you. And my final question relates to, does this really matter? We have to interpret this study in the context of the Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study (CROSS) trial that was just reported this year, which included T2 N0 patients in their induction strategy. In a large series of 366 patients with a relatively nontoxic induction program, there was a dramatic doubling in survival with induction therapy for locally advanced esophageal cancer, which in their study included T2 N0 patients. In fact, one of your last slides indicated that the surgeons of America are voting with their feet, and now more than 50% of the people with T2 N0 lesions are having induction therapy. I must say that in my center, our oncologists strongly believe all T2 N0 patients should have induction therapy because of the very high likelihood of missed N1 disease, as you have shown elegantly in this study. So, again, does this really matter?
DR CRABTREE: Another excellent question. It was interesting, in the CROSS trial, if you look at their hazard ratio model, induction therapy actually mostly favored the patients who were clinical N0, and there was no survival advantage in the patients who were clinically N1. So it could be that in this subset of patients with, I guess, a lower burden of nodal disease in this setting, occult nodal disease, may be the patients who would potentially benefit from this induction therapy. I agree, I think potentially now I will likely change my practice to offer these patients induction therapy, although ultimately it would be nice to see long-term survival data in this subset to really confirm that. But I think this is another piece of the puzzle that supports the CROSS trial data as well. I will say, as in the database, only 15% of the patients in the CROSS trial were T2 N0. So it was a small subset of patients.
DR DOUGLAS E. WOOD (Seattle, WA): That is a great presentation and delivered some new insights, and Dr Wright correctly pointed out the limitation of the staging modalities over this time period, which is significantly limiting. My biggest question has to do with institutional variation or experience and its impact on reliability. I know that wasn't part of your study, and I don't even know whether maybe there are enough numbers to be valid, but we certainly know with EUS that operator experience is a very important contributor to accuracy. The biggest argument I would say from your paper for induction therapy for clinical T2 is that most of the clinical T2 patients are not pathologic T2, just as Dr Wright pointed out. But if in an institution you had a high degree of clinical accuracy, and actually, mostly did have T2 N0, would that potentially be a reason to continue your strategy of primary surgery rather than induction therapy, which is largely driven by the unexpected presence of N1 disease? DR CRABTREE: Dr Wood, thank you. Actually if you look at the data, it is a coin toss: about 50% are actually going to be pathologic T1 or T2 N0 and about 50% are going to have a higher pathologic stage.
With regards to the experience of centers, it is still a little hard to tease that out in the database. At the completion of this study, 108 centers were participating in the thoracic database. Only about 20 centers contributed more than 10 patients to this actual study. So 100 or so studies had less than 10 patients. I can't tell you about the details of how they performed EUS, the experience with EUS, but it is intuitive. The data in the endoscopy literature clearly show that a greater experience improves the accuracy of EUS.
DR STEVEN R. DEMEESTER (Los Angeles, CA): I enjoyed your paper very much. First, a comment: The most important risk factor for dying from esophageal cancer is lymph node disease. So if you look at your group that were overstaged, those less than T2 N0, add to those the true T2 N0, and then add any T3 N0 patients, who also have a very good survival rate because they are node-negative, the subgroup that really might benefit from neoadjuvant therapy, the group at risk for systemic disease (ie those with nodal disease) becomes very small.
My question is, in the STS database, do we know what happens to the patients who receive induction therapy? If you look at the CROSS trial and every published trial on neoadjuvant therapy, a number drop out because of disease progression during therapy or because they are too sick to subsequently have their surgery. Does the STS database know how many patients never made it to surgery with relatively early-stage disease for which they were getting toxic chemotherapy? DR CRABTREE: Dr DeMeester, thank you. That is an excellent point. I saw you are also doing the pro-con talk on the treatment of clinical T2 N0 disease. No, the only patients that we have in the database are the patients who actually underwent esophagectomy. It was interesting in the CROSS trial that the rate of fallout was only about 6%, and most of those patients were from disease progression.
DR HOFSTETTER:
Talking about better staging, we have to enter into a discussion about esophageal mucosal resection (EMR) and using EMR more liberally to try and delineate those T0 and T1 patients. So I think the key to us getting rid of that 25% overdiagnosis is the liberal use of diagnostic EMR.
DR CRABTREE: Thank you, Dr Hopstetter. I think we do have to be careful, I agree with the ones that are specifically T1, attempting to determine whether they are T1a or T1b. You potentially increase the risk of perforation if you do EMR on a T2 lesion.
DR HIRAN FERNANDO (Boston, MA): I would echo Dr DeMeester's comment that we have to focus on the patients who have nodal disease. There is about a 10% difference between your two groups of patients who were found to have nodal disease. The other factor to take into account is that after induction therapy, your ability to get a good lymph node dissection and your total lymph node counts are going to be less. So it may just be that you are not removing as many lymph nodes, and you may be understaging patients as well. So the question is, does it really matter whether we give induction therapy or not for these patients?
DR CRABTREE: No doubt we need to look at long-term survival to look at the relative benefit of induction therapy, but I don't have the data on the adequacy of nodal dissection in the induction therapy group or primary surgical group. I think it does matter that we are potentially offering surgery to a quarter of patients with T1 N0 disease. That might be a group that we would like to avoid induction therapy in.
DR FERNANDO: But the actual difference is only about 10% in patients who had nodal disease between the two groups, and that may have been a factor related to the adequacy of that nodal dissection.
DR CRABTREE: Perhaps. I don't have the data to confirm or deny that. Ultimately, the only way to answer this question is to determine the impact of induction therapy on long-term survival in clinical T2 N0 patients. These data don't afford us that opportunity.
DR JOHN R. BENFIELD (Los Angeles, CA): As we are approaching the 50th anniversary of The Society of Thoracic Surgeons, these excellent papers cause me to reflect about the history of the database that is now about 25 years old. The New York Times had reported misleading cardiac surgery outcomes that were not risk-adjusted. The late Paul Ebert, a Past President of the American Association for Thoracic Surgery, and other database visionaries, saw the need for risk-adjusted outcomes to inform our patients, and to guide us in therapy. This database is widely acknowledged for its groundbreaking originality and importance. It is the kind of initiative that should be brought forward to the press that so often portrays physicians as greedy and self-serving. The public would appreciate knowing that our primary and over-riding interested is in the welfare of our patients.
DR CRABTREE: Thank you very much, sir.
